Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“10.8 months vs 3.2 months. Adding camrelizumab + rivoceranib to TACE in unresectable HCC increased progression-free survival nearly threefold.
A new evolution in TACE-based therapies may be beginning.
Biological rationale:
- TACE induces tumor necrosis and may increase neoantigen release, potentially priming an immune response.
- However, it also creates hypoxia and VEGF upregulation, promoting angiogenesis.
- Anti-VEGF therapy (rivoceranib) may normalize the tumor microenvironment.
- PD-1 blockade (camrelizumab) may further amplify the antitumor immune response.
Together, locoregional therapy + immunotherapy + anti-angiogenic therapy may represent the next therapeutic paradigm in HCC.
Another key issue: Could TACE + IO + anti-VEGF become a new backbone strategy for intermediate-stage HCC, similar to what systemic combinations did in advanced disease?
An important question remains: Will this strategy also translate into an overall survival benefit, or is the effect mainly limited to PFS?”
Title: Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial
Authors: Hai-Dong Zhu, Wei-Jun Fan, Chang Zhao, Song Wang, Yu-Liang Li, Zhi-Cheng Jin, Zhe-Wei Zhang, Jin-He Guo, Hong-Tao Cheng, Qi Zhang, Jian Lu, Yong-Yi Zeng, Wei-Fu Lv, Hao Xu, Hai-Bo Shao, Wei-Guo Xu, Xu-Ya Zhao, Shan-Zhi Gu, Hai-Lan Lin, Wen-Heng Zheng, Long-Zhen Piao, Yu-Sheng Song, Jian-Bo Zhao, Yuan-Cheng Wang, Zhi-Guo Hou, Ying Sun, Ni Guan, Ming Huang, Wei-Zhu Yang, Jian-Song Ji, Gao-Jun Teng
Read the Full Article.
Other articles featuring Ahmet Dirican on OncoDaily.